【摘要】：目的:了解西那卡塞治療繼發(fā)性甲狀旁腺功能亢進癥(SHPT)的臨床研究進展。方法:查閱近年來國內(nèi)外相關文獻,就西那卡塞對血管鈣化的影響、致心血管事件和死亡事件的研究進行歸納和總結(jié),并對西那卡塞潛在的生存獲益機制進行分析。結(jié)果:西那卡塞可降低SHPT患者甲狀旁腺激素水平,提高其對礦物質(zhì)和骨代謝的控制力。盡管初期的研究結(jié)果尚無定論,但以ADVANCE和EVOLVE為代表的多項隨機對照試驗結(jié)果均提示西那卡塞對延緩心血管鈣化進程、降低心血管事件發(fā)生率、降低死亡率和降低骨折風險等方面均有潛在作用。這些陽性的研究成果與西那卡塞對骨代謝和血管鈣化的有益效應數(shù)據(jù)具有一致性,為西那卡塞的潛在生存獲益作用提供了支持。結(jié)論:現(xiàn)有研究結(jié)果仍缺乏決定性的證據(jù),仍需進一步驗證西那卡塞對慢性腎臟病所致SHPT患者臨床結(jié)局的有利作用。
[Abstract]:Objective: to investigate the clinical progress in the treatment of (SHPT) with secondary hyperparathyroidism. Methods: the effects of Sinakaser on vascular calcification, cardiovascular events and death events were summarized, and the mechanism of Sinacase's potential survival and benefit was analyzed. Results: cilazepine could decrease the level of parathyroid hormone and improve the control of mineral and bone metabolism in SHPT patients. Although the results of the initial study are not conclusive, the results of several randomized controlled trials, represented by ADVANCE and EVOLVE, suggest that Sinakaser can delay the process of cardiovascular calcification and reduce the incidence of cardiovascular events. Reducing mortality and reducing fracture risk have potential effects. These positive results are consistent with the data on the beneficial effects of Sinakaser on bone metabolism and vascular calcification, and support the potential survival benefits of Sinakaser. Conclusion: there is still no conclusive evidence in the present study, and it is necessary to further verify the beneficial effect of Sinakasai on the clinical outcome of patients with SHPT caused by chronic kidney disease.
【作者單位】： 呼倫貝爾市人民醫(yī)院臨床藥學部;內(nèi)蒙古民族大學呼倫貝爾醫(yī)學院;呼倫貝爾市中蒙醫(yī)院藥劑科;
【分類號】：R582.1

【相似文獻】

中國碩士學位論文全文數(shù)據(jù)庫 前1條

1 尹鶴立;西那卡塞對繼發(fā)性甲狀旁腺功能亢進癥透析患者療效及死亡率影響的Meta分析[D];廣西醫(yī)科大學;2017年

，

本文編號：2411542